文献速递炎症性肠病

RAINBOW-IBD研究:炎症性肠病生物制剂升阶梯与降阶梯的频率和有效性

Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDA.
PubMed 文献 · Aliment Pharmacol Ther · 2025-08-08

基于ENEIDA注册研究19,720例使用生物制剂的炎症性肠病患者,26%需升阶梯,临床缓解再捕获率32%-49%,24个月持久性66%-88%;669例降阶梯,缓解维持率75%-100%,12个月持久性82%-90%;再升阶梯对多数患者有效。

要点

  • 升阶梯频率每患者年5%-12%,临床缓解再捕获率32%-49%,24个月持久性66%-88%。
  • 降阶梯669例,缓解维持率75%-100%,12个月持久性82%-90%。
  • 再升阶梯对多数复发患者有效。

核心结论

  • 长期来看部分IBD患者需生物制剂升阶梯,常可再捕获持久临床缓解;降阶梯对部分患者可行;复发后再升阶梯通常有效。

研究设计与样本

  • 基于ENEIDA注册(GETECCU)的多中心真实世界研究,纳入19,720例使用生物制剂的IBD患者,分析升阶梯和降阶梯的频率、有效性及持久性。

主要发现

  • 5,096例(26%)接受升阶梯,每患者年频率:英夫利西单抗5%、阿达木单抗7%、戈利木单抗7%、维得利珠单抗10%、乌司奴单抗12%。
  • 升阶梯后临床缓解再捕获率32%-49%,24个月持久性66%-88%。
  • 降阶梯669例,每患者年频率:英夫利西单抗6%、阿达木单抗9%、戈利木单抗5%、维得利珠单抗6%、乌司奴单抗3%。
  • 降阶梯后缓解维持率75%-100%,12个月持久性82%-90%。

关键数值与推荐

  • 药物停用相关因素:英夫利西单抗与既往生物制剂暴露和病程相关;阿达木单抗与单药治疗相关;乌司奴单抗与溃疡性结肠炎相关。
  • 降阶梯后复发相关因素:英夫利西单抗与生物制剂暴露相关;阿达木单抗与降阶梯时年龄相关。

临床怎么用

  • 升阶梯可有效再捕获临床缓解且持久性较好,再升阶梯对复发患者通常有效,降阶梯在部分患者中可行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Real-world data on dose escalation/de-escalation in inflammatory bowel disease (IBD) are scarce. AIMS: To assess the frequency, effectiveness and durability of escalation/de-escalation of infliximab, adalimumab, golimumab, vedolizumab and ustekinumab in IBD, and to identify factors influencing relapse and drug discontinuation and re-escalation efficacy. METHODS: We included patients from the ENEIDA registry of GETECCU who were exposed to biologics and analysed escalations/de-escalations. We assessed the impact of variables on durability, drug discontinuation and relapse after escalation/de-escalation. RESULTS: Of 19,720 patients on biologics, 5096 (26%) underwent dose escalation. Frequency of escalation per patient-year was 5% (infliximab), 7% (adalimumab), 7% (golimumab), 10% (vedolizumab) and 12% (ustekinumab). Clinical remission was recaptured in 32%-49% of patients. Durability of escalation (24 months) ranged from 66% to 88%. Drug discontinuation was associated with previous biologic exposure and disease duration (infliximab), monotherapy (adalimumab) and ulcerative colitis (ustekinumab). There were 669 de-escalations. The frequency per patient-year was 6%, 9%, 5%, 6% and 3% for infliximab, adalimumab, golimumab, vedolizumab and ustekinumab. Maintenance of remission after de-escalation was observed in 75%-100%. Durability of de-escalation (12 months) was 82%-90%. Factors associated with relapse were biologic exposure (infliximab) and age at de-escalation (adalimumab). Re-escalation benefited most patients. CONCLUSIONS: In the long term, some patients with IBD need biologic escalation, which frequently recaptures durable clinical remission. De-escalation is feasible in some patients. Re-escalation is generally effective after relapse.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Rubín de Célix C, Ricart E, Martín-Arranz MD, et al. Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDA. Aliment Pharmacol Ther. 2025. PMID: 40778752. doi:10.1111/apt.70312

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。